Additional information:
ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research.|Product information|CAS Number: 1377897-01-2|Molecular Weight: 339.43|Formula: C21H25NO3|Chemical Name: (4-hydroxy-3, 4-dihydro-1H-isoquinolin-2-yl)-[3-(3-hydroxy-3-methylbutyl)phenyl]methanone|Smiles: CC(C)(O)CCC1C=CC=C(C=1)C(=O)N1CC2=CC=CC=C2C(O)C1|InChiKey: HYVUFYJZMRRTOP-UHFFFAOYSA-N|InChi: InChI=1S/C21H25NO3/c1-21(2,25)11-10-15-6-5-8-16(12-15)20(24)22-13-17-7-3-4-9-18(17)19(23)14-22/h3-9,12,19,23,25H,10-11,13-14H2,1-2H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Avapritinib} medchemexpress|{Avapritinib} c-Kit|{Avapritinib} Purity & Documentation|{Avapritinib} In Vitro|{Avapritinib} custom synthesis|{Avapritinib} Epigenetics} |Shelf Life: ≥12 months if stored properly.{{SARS-CoV-2 S2 Protein (HEK293, His)} web|{SARS-CoV-2 S2 Protein (HEK293, His)} Protocol|{SARS-CoV-2 S2 Protein (HEK293, His)} Purity|{SARS-CoV-2 S2 Protein (HEK293, His)} manufacturer|{SARS-CoV-2 S2 Protein (HEK293, His)} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:28038441 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ERD03 inhibits the binding of G-rich RNA and EXOSC3 with ~18% inhibition at 50 μM. ERD03 (50 μM; 5 days) causes significant spinal curvature and recapitulates PCH1B phenotype in development in zebrafish embryos. ERD03 (50 μM) induces a ~6-fold upregulation of ataxin1b mRNA and results in a minor accumulation of ataxin1a mRNA in embryos. ERD03 induces an atrophy of the zebrafish cerebellum and results in zebrafish cerebella half the size of control brains in DMSO.|Products are for research use only. Not for human use.|

Additional information:
Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia.|Product information|CAS Number: 57149-08-3|Molecular Weight: 465.41|Formula: C24H30Cl2N2O3|Chemical Name: 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol dihydrochloride|Smiles: Cl.Cl.COC1=CC=CC=C1N1CCN(CC(O)COC2=CC=CC3=CC=CC=C32)CC1|InChiKey: HZVCEQMJXMUXJF-UHFFFAOYSA-N|InChi: InChI=1S/C24H28N2O3.{{Miconazole} medchemexpress|{Miconazole} Antibiotic|{Miconazole} Protocol|{Miconazole} Purity|{Miconazole} supplier|{Miconazole} Autophagy} 2ClH/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23;;/h2-12,20,27H,13-18H2,1H3;2*1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Daratumumab} site|{Daratumumab} CD38|{Daratumumab} Protocol|{Daratumumab} Formula|{Daratumumab} supplier|{Daratumumab} Cancer} |Shelf Life: ≥12 months if stored properly.PMID:25016614 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Naftopidil dihydrochloride suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Naftopidil dihydrochloride (10 μM for PCa cells, 0.1-10 μM for PrSC; 3 days) shows growth inhibitory effects on PCa cells and PrSC. Naftopidil dihydrochloride (50 μM for E9 cells, 25 μM for PrSC; 48 hours) increases the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.|In Vivo:|Naftopidil dihydrochloride (10 mg/kg; p.o; daily; for 28 days) decreases microvessel density (MVD) in E9+PrSC tumors mice model.|Products are for research use only. Not for human use.|

Additional information:
Syringetin-3-O-glucosid (Syringetin 3-O-β-D-glucoside), a flavonol glycoside, shows relatively weak DPPH and ABTS radical scavenging activity.|Product information|CAS Number: 40039-49-4|Molecular Weight: 508.43|Formula: C23H24O13|Chemical Name: 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one|Smiles: COC1=CC(=CC(OC)=C1O)C1OC2=CC(O)=CC(O)=C2C(=O)C=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O|InChiKey: JMFWYRWPJVEZPV-AVGVHVDKSA-N|InChi: InChI=1S/C23H24O13/c1-32-12-3-8(4-13(33-2)16(12)27)21-22(18(29)15-10(26)5-9(25)6-11(15)34-21)36-23-20(31)19(30)17(28)14(7-24)35-23/h3-6,14,17,19-20,23-28,30-31H,7H2,1-2H3/t14-,17-,19+,20-,23+/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{FMK-MEA} web|{FMK-MEA} Inhibitor|{FMK-MEA} Activator|{FMK-MEA} Purity & Documentation|{FMK-MEA} In stock|{FMK-MEA} custom synthesis} |Shelf Life: ≥12 months if stored properly.{{Flubendazole} web|{Flubendazole} Autophagy|{Flubendazole} Protocol|{Flubendazole} In Vivo|{Flubendazole} custom synthesis|{Flubendazole} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23489613 |Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
Mahanine is a carbazole alkaloid with various biological properties.PMID:23489613 Mahanine is a potent anticancer agent against different types of cancer cells. Mahanine exhibits antileishmanial activity and can be used for Leishmania infection treatment research.|Product information|CAS Number: 28360-49-8|Molecular Weight: 347.45|Formula: C23H25NO2|Chemical Name: (3R)-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-3H,11H-pyrano[3,2-a]carbazol-9-ol|Smiles: CC(C)=CCC[C@]1(C)C=CC2C3NC4=CC(O)=CC=C4C=3C=C(C)C=2O1|InChiKey: DWMBXHWBPZZCTN-HSZRJFAPSA-N|InChi: InChI=1S/C23H25NO2/c1-14(2)6-5-10-23(4)11-9-18-21-19(12-15(3)22(18)26-23)17-8-7-16(25)13-20(17)24-21/h6-9,11-13,24-25H,5,10H2,1-4H3/t23-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Mahanine (0-50 µM; 24 or 48 hours) induces a dose-dependent decrease in cell viability of AG83 promastigotes after 24 hr and 48 hr; the IC50 values were 16.7±1.7 µM and 11.5±0.8 µM respectively. In a drug resistant GE1 strain, Mahanine treatment exhibits dose-dependent cell death in 24 and 48 hr treatment with IC50 values 40.3±2.2 µM and 29.1±1.3 µM respectively. Mahanine (5.0 and 10 µM; 24 hours) exhibits increased accumulation of cells at G2/M phase being 39.0±1.90% and 41.0±2.10% respectively compared to untreated promastigotes (35.3 ± 2.60%) in AG83 promastigote . Mahanine (25 µM; 24 hours) exhibitssignificantly increased intracellular ROS level within 20 min (MFI being 889 ± 26) which reached to 1288 ± 56 after one hour compared to the basal level (604 ± 34) in untreated promastigote. H2DCFDA positivity was measured by FACS.|In Vivo:|Mahanine (oral gavage; 20 mg/kg/40 mg/kg; b.w/day; 5 days) results in 89.1±4.1% reductions in parasite burden at 20 mg/kg, and leads to 96.2±0.3% reductions in parasite burden at 40 mg/kg in a well-established acute model to control Leishmania infection.|Products are for research use only. Not for human use.|

Additional information:
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.|Product information|CAS Number: 914454-01-6|Molecular Weight: 4917.24|Formula: C212H328N52O80S|Chemical Name: (2R, 4S, 5R, 6S)-5-acetamido-2-[[(2R, 3R, 4S, 5R, 6S)-6-[(2R, 3S, 4R, 5R, 6R)-5-acetamido-6-[[(3S)-3-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S, 3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S, 3R)-2-[[(2S)-2-[[(2S, 3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3, 4, 5-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-6-[(2S, 3R)-2, 3, 4-trihydroxybutyl]oxane-2-carboxylic acid;acetate|Smiles: CC[C@H](C)[C@H](NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@H](C[C@H](O)[C@H](O)CO)O3)C(O)=O)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1NC(C)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O.{{p-Coumaric acid} site|{p-Coumaric acid} Endogenous Metabolite|{p-Coumaric acid} Purity & Documentation|{p-Coumaric acid} In Vivo|{p-Coumaric acid} custom synthesis|{p-Coumaric acid} Cancer} CC(O)=O|InChiKey: YGHQSTMXYLWAJN-ZAVVHXGLSA-N|InChi: InChI=1S/C210H324N52O78S.{{Anti-Mouse CD209b Antibody} medchemexpress|{Anti-Mouse CD209b Antibody} Protocol|{Anti-Mouse CD209b Antibody} References|{Anti-Mouse CD209b Antibody} supplier|{Anti-Mouse CD209b Antibody} Autophagy} C2H4O2/c1-18-101(10)162(200(328)240-123(54-60-159(292)293)185(313)245-130(75-110-81-220-114-41-26-25-40-112(110)114)190(318)242-125(70-97(2)3)187(315)232-116(43-28-30-63-212)180(308)246-131(77-149(278)255-203-166(230-107(16)273)168(297)171(146(94-269)337-203)339-207-170(299)169(298)167(296)147(338-207)95-336-210(208(334)335)80-143(275)165(229-106(15)272)145(340-210)79-142(274)144(276)93-268)176(304)223-83-150(279)221-87-154(283)259-65-32-45-138(259)197(325)252-136(91-266)196(324)250-134(89-264)177(305)225-84-151(280)227-103(12)204(331)261-67-34-47-140(261)206(333)262-68-35-48-141(262)205(332)260-66-33-46-139(260)198(326)249-133(88-263)172(215)300)257-192(320)128(73-108-36-21-19-22-37-108)244-188(316)126(71-98(4)5)241-181(309)117(44-31-64-219-209(216)217)239-199(327)161(100(8)9)256-173(301)102(11)228-178(306)120(51-57-156(286)287)235-183(311)121(52-58-157(288)289)236-184(312)122(53-59-158(290)291)237-186(314)124(61-69-341-17)238-182(310)119(49-55-148(214)277)234-179(307)115(42-27-29-62-211)233-194(322)135(90-265)251-189(317)127(72-99(6)7)243-191(319)132(78-160(294)295)247-195(323)137(92-267)253-202(330)164(105(14)271)258-193(321)129(74-109-38-23-20-24-39-109)248-201(329)163(104(13)270)254-153(282)86-224-175(303)118(50-56-155(284)285)231-152(281)85-222-174(302)113(213)76-111-82-218-96-226-111;1-2(3)4/h19-26,36-41,81-82,96-105,113,115-147,161-171,203,207,220,263-271,274-276,296-299H,18,27-35,42-80,83-95,211-213H2,1-17H3,(H2,214,277)(H2,215,300)(H,218,226)(H,221,279)(H,222,302)(H,223,304)(H,224,303)(H,225,305)(H,227,280)(H,228,306)(H,229,272)(H,230,273)(H,231,281)(H,232,315)(H,233,322)(H,234,307)(H,235,311)(H,236,312)(H,237,314)(H,238,310)(H,239,327)(H,240,328)(H,241,309)(H,242,318)(H,243,319)(H,244,316)(H,245,313)(H,246,308)(H,247,323)(H,248,329)(H,249,326)(H,250,324)(H,251,317)(H,252,325)(H,253,330)(H,254,282)(H,255,278)(H,256,301)(H,257,320)(H,258,321)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)(H,294,295)(H,334,335)(H4,216,217,219);1H3,(H,3,4)/t101-,102-,103-,104+,105+,113-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144+,145-,146+,147+,161-,162-,163-,164-,165+,166+,167-,168+,169-,170+,171+,203+,207-,210+;/m0.PMID:24059181 /s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 66.66 mg/mL (15.70 mM). H2O : 1 mg/mL (0.24 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|In human umbilical vein endothelial cells, Exendin-4 significantly increases NO production, endothelial NO synthase (eNOS) phosphorylation, and GTP cyclohydrolase 1 (GTPCH1) level in a dose-dependent manner. Exendin-4 shows cytotoxic effects to MCF-7 breast cancer cells with IC50 of 5 μM at 48 hour.|In Vivo:|Both low- and high-dose Exendin-4 treatment in ob/ob mice improve serum ALT and reduce serum glucose, and calculated HOMA scores compared with control. Exendin-4-treated ob/ob mice sustain a marked reduction in the net weight gain in the final 4 weeks of the study period. Animals treated with Exendin-4 have more pancreatic acinar inflammation, more pyknotic nuclei and weigh significantly less than control rats. Exendin-4 treatment is associated with lower leptin levels as well as lower HOMA values in rats. Exenatide causes dose-dependent relaxation of rat thoracic aorta, which is evoked via the GLP-1 receptor and is mediated mainly by H2S but also by NO and CO.|Products are for research use only. Not for human use.|

Additional information:
Azatadine is a first-generation antihistamine and anticholinergic. It has been succeeded by both loratadine and desloratadine.|Product information|CAS Number: 3964-81-6|Molecular Weight: 290.40|Formula: C20H22N2|Synonym:|Optimine|Chemical Name: 2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaene|Smiles: CN1CCC(CC1)=C1C2=NC=CC=C2CCC2=CC=CC=C21|InChiKey: SEBMTIQKRHYNIT-UHFFFAOYSA-N|InChi: InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Risperidone} site|{Risperidone} Neuronal Signaling|{Risperidone} Protocol|{Risperidone} Data Sheet|{Risperidone} supplier|{Risperidone} Epigenetics} |Shelf Life: ≥12 months if stored properly.{{Bicuculline} MedChemExpress|{Bicuculline} GABA Receptor|{Bicuculline} Biological Activity|{Bicuculline} Data Sheet|{Bicuculline} supplier|{Bicuculline} Epigenetic Reader Domain} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:24578169 |Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
Chemical dimerizer used in auxin-inducible degron (AID) systems. Induces degradation of a target protein tagged with the auxin-receptor F-box protein Tir1 E3 ligase AID in human colorectral cancer and mouse ES cells or tagged with AFB2 in A431 cells. Endogenous plant hormone.|Product information|CAS Number: 87-51-4|Molecular Weight: 175.18|Formula: C10H9NO2|Synonym:|indolylacetic acid|1H-Indole-3-acetic acid|indoleacetic acid|heteroauxin|IAA|Chemical Name: indole-3-acetic acid|Smiles: OC(=O)CC1=CNC2=CC=CC=C21|InChiKey: SEOVTRFCIGRIMH-UHFFFAOYSA-N|InChi: InChI=1S/C10H9NO2/c12-10(13)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H,12,13)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 35 mg/mL(199.79 mM). Water: undefined.|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Eugenol} medchemexpress|{Eugenol} Apoptosis|{Eugenol} Purity & Documentation|{Eugenol} In Vitro|{Eugenol} custom synthesis|{Eugenol} Autophagy} |Shelf Life: ≥12 months if stored properly.PMID:36628218 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Indole-3-acetic acid (IAA) induces cytotoxicity in fibroblasts, neutrophils, and several cancer lineages in vitro.|In Vivo:|IAA administration in pregnant rats during days 12-14 might selectively affect the S phase neurons and lead to their apoptosis in the neuroepithelium. It induces microencephaly in rats.|References:|Furukawa S, et al. Toxicol Pathol. 2004, 32(6):659-67.Products are for research use only. Not for human use.|

Additional information:
GSK256066 is a potent and selective PDE4 inhibitor that can be given by inhalation, minimising the potential for side effects. GSK256066 demonstrated a protective effect on the EAR and LAR. GSK256066 is a slow and tight binding inhibitor of PDE4B (apparent IC(50) 3.2 pM; steady-state IC(50) Product information|CAS Number: 801312-28-7|Molecular Weight: 518.58|Formula: C27H26N4O5S|Synonym:|GSK256066|GSK-256066|GSK 256066|Related CAS Number:|801315-14-0 (HCl)|1415560-64-3 (TFA)|Chemical Name: 6-[3-(dimethylcarbamoyl)benzenesulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide|Smiles: CC1=CC(=CC2=C1N=CC(C(N)=O)=C2NC1=CC(=CC=C1)OC)S(=O)(=O)C1=CC(=CC=C1)C(=O)N(C)C|InChiKey: JFHROPTYMMSOLG-UHFFFAOYSA-N|InChi: InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Solubility (25°C) DMSO: 5 mg/mL(9.64 mM). Water: Insoluble.|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|GSK256066 is a slow and tight binding inhibitor of PDE4B with apparent IC50 of 3.2 pM. GSK256066 is an extremely potent inhibitor of LPS-stimulated TNFα production in PBMCs with pIC50 of 11.0 and IC50 of 10 pM and human whole-blood cultures with pIC50 of 9.90 and IC50 of 126 pM. GSK256066 is highly selective for PDE4 (>3.8 × 105-fold versus PDE1, PDE2, PDE3, PDE5, and PDE6 and >2.5 × 103-fold against PDE7). GSK256066 inhibits PDE4 isoforms A-D with equal affinity.|In Vivo:|GSK256066 inhibits the LPS-induced pulmonary neutrophilia with an ED50 of 1.1 μg/kg, achieving maximal inhibition of 72% at 30 μg/kg when given in the aqueous suspension.PMID:26895888 GSK256066 inhibits the LPS-induced pulmonary neutrophilia with ED50 of 2.9 μg/kg, achieving maximal inhibition of 62% when given in the dry powder formulation. GSK256066 shows a moderate plasma clearance of 39 ml/min/kg, a moderate volume of distribution of 0.8 L/kg, and a relatively short half-life of 1.1 hour in the male CD rat. GSK256066 sustains at a high lung concentration of 2.6 μg/g after intra-tracheal administration as an aqueous suspension at a dose of 30 μg/kg in rats. GSK256066 (10 μg/kg) is administered intratracheally at different times (2, 6, 12, 18, 24, and 36 hours) before LPS administration, inhibiting LPS-Induced Pulmonary Neutrophilia in rat lipopolysaccharide (LPS)-induced models of acute pulmonary inflammation. GSK256066 (0.3–100 μg/kg) inhibits LPS-induced increases in exhaled nitric oxide with ED50 of 35 μg/kg in rat. GSK256066 (10 μg/kg) is administered half a hour before OVA administration in rat, inhibiting OVA-induced pulmonary eosinophilia with ED50 of 0.4 μg/kg. GSK256066 administered intratracheally as a dry powder blended in respiratory-grade lactose at doses of 3 to 100 μg/kg 2 hours before inhaled LPS challenge in ferrets, inhibiting LPS-induced pulmonary neutrophilia with ED50 of 18 μg/kg without inducing emetic episodes.|References:|Nials AT, et al. J Pharmacol Exp Ther, 2011, 337(1), 137-144.Woodrow MD, et al. Bioorg Med Chem Lett, 2009, 19(17), 5261-5265.Tralau-Stewart CJ, et al. J Pharmacol Exp Ther, 2011, 337(1), 145-154.Products are for research use only. Not for human use.|

Additional information:
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and u-receptor agonist.|Product information|CAS Number: 519-02-8|Molecular Weight: 248.36|Formula: C15H24N2O|Synonym:|Matridin-15-one|NSC 146051|NSC146051|NSC-146051|Chemical Name: (1R, 2R, 9S, 17S)-7, 13-diazatetracyclo[7.{{DBCO-Biotin} MedChemExpress|{DBCO-Biotin} PROTAC Linkers|{DBCO-Biotin} Epigenetics|{DBCO-Biotin} Protocol|{DBCO-Biotin} In stock|{DBCO-Biotin} manufacturer} 7.1.0, .0, ]heptadecan-6-one|Smiles: O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@H]43|InChiKey: ZSBXGIUJOOQZMP-JLNYLFASSA-N|InChi: InChI=1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 49 mg/mL(197.29 mM). Water: 11 mg/mLwarmed(44.29 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Guanidine} medchemexpress|{Guanidine} Endogenous Metabolite|{Guanidine} Purity & Documentation|{Guanidine} Formula|{Guanidine} custom synthesis|{Guanidine} Epigenetics} |Shelf Life: ≥12 months if stored properly.PMID:24605203 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Matrine((+)-Matrine) is an alkaloid found in plants from the Sophora family, which has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor agonist. Matrine significantly inhibites the growth of human non-small cell lung cancer A549 and hepatoma SMMC-7721 cells and induces apoptosis by strongly reducing the viability and the ratio of Bcl-2/Bax protein in A549 cells. matrine may stimulate the descending dynorphinergic neuron, resulting in the stimulation of kappa-opioid receptors (KORs) in the spinal cord, and this phenomenon in turn produces the antinociception in mice.|In Vivo:|LD50: Mice 157mg/kg (i.p.)|References:|Wang XY, et al. Nanfang Yike Daxue Xuebao, 2010, 30(9), 2154-2155.Higashiyama K, et al. Biol Pharm Bull, 2005, 28(5), 845-848.Zhang Y, et al. Cytotechnology, 2009, 59(3), 191-200.Products are for research use only. Not for human use.|

Additional information:
Chondroitin sulfate, one of five classes of glycosaminoglycans, has been widely used in the treatment of osteoarthritis. Chondroitin sulfate reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, iNOS and MMPs.|Product information|CAS Number: 9007-28-7|Synonym:|Chondroitin polysulfate|Chemical Name: Chondroitin sulfate|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: H2O : ≥ 50 mg/mL|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Chondroitin sulfate is a class of sulfated glycosaminoglycans that are linear polysaccharides consisting of repeating disaccharide units composed of uronic acid and N-acetylhexosamine. Several pathogens including parasites, bacteria, and viruses have been shown to utilize cell surface chondroitin sulfate chains to attach to and infect host cells[1]. Chondroitin sulfate occurs naturally in the extracellular matrix of connective tissues, e.g., bone, cartilage, skin, ligaments and tendons. Chondroitin sulfate has been shown to elicit a range of beneficial effects: anti-inflammatory effects, an increase in type II collagen and proteoglycans, a reduction in bone resorption and a better anabolic/catabolic balance in chondrocytes[2]. A large range of chondroitin sulfate concentrations has been used (e.g. 12.5 to 2000 mg/mL, but generally less than200 mg/mL) in in vitro studies. Chondroitin sulfate (200 mg/mL) decreases the chondrocyte susceptibility to single nucleotide polymorphism-induced apoptosis[3]. Chondroitin sulfate reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, iNOS, MMPs[4].|In Vivo:|The high content of chondroitin sulfate in the aggrecan plays a major part in allowing cartilage to resist tensile stresses during various loading conditions by providing this tissue with resistance and elasticity. It has been shown that chondroitin sulphate interferes with the progression of structural changes in joint tissues and is used in the management of patients with osteoarthritis[3].{{Protein G Agarose} web|{Protein G Agarose} Biological Activity|{Protein G Agarose} Formula|{Protein G Agarose} custom synthesis|{Protein G Agarose} Cancer} Chondroitin sulfate is mostly administered orally at doses ranging from 800 to 1200mg/day.{{Apocynin} MedChemExpress|{Apocynin} Metabolic Enzyme/Protease|{Apocynin} Biological Activity|{Apocynin} Formula|{Apocynin} manufacturer|{Apocynin} Cancer} Chondroitin sulfate is rapidly absorbed by the gastrointestinal tract.PMID:23833812 The absorbed chondroitin sulfate reaches the blood compartment as 10% chondroitin sulfate and 90% depolymerized low-molecular-weight derivatives[5].|References:|Mikami T, et al. Biosynthesis and function of chondroitin sulfate. Biochim Biophys Acta. 2013 Oct;1830(10):4719-33.Martel-Pelletier J, et al.Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015 Mar 6;20(3):4277-89.Monfort J, et al. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis. 2008 Jun;67(6):735-40.Campo GM, et al. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J Cell Biochem. 2009 Jan 1;106(1):83-92.Henrotin Y, et al. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinicalrecommendations. Ther Adv Musculoskelet Dis. 2010 Dec;2(6):335-48.Products are for research use only. Not for human use.|